Scarica l'app Stockscreener
14.32
7.31%
-1.175
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Erasca Inc Borsa (ERAS) Ultime notizie
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015 - simplywall.st
Erasca (ERAS) to Release Earnings on Thursday - MarketBeat
Stifel raises Erasca stock price target to $20 on China expansion - Investing.com
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 - Investing.com Nigeria
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau - Bitget
Global cancer drug rights: Erasca takes ERAS-0015 worldwide - Stock Titan
Erasca Inc stock hits 52-week high at $14.63 - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Hits New 52-Week HighTime to Buy? - MarketBeat
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - 24/7 Wall St.
Growth Recap: How interest rate cuts could boost Erasca Inc. stock2025 Technical Overview & Community Verified Watchlist Alerts - Naître et grandir
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - The Globe and Mail
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com
Erasca’s chief medical officer Morris sells $300k in ERAS stock - Investing.com
Erasca (ERAS) Sees Target Price Raised By Clear Street To $20 | - GuruFocus
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Sahm
Clear Street raises Erasca stock price target on combination trial deal - Investing.com Australia
Erasca and Tango Therapeutics Partner to Study ERAS-007 and Vopimetostat Combination for MTAP-Deleted Cancers - geneonline.com
Assessing Tango Therapeutics (TNGX) Valuation After Earnings Update And New Erasca Trial Collaboration - simplywall.st
Tango rises after Q4 results, clinical pact with Erasca - Seeking Alpha
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat - Bitget
Biopharmaceutical company Erasca, Inc. (NASDAQ: ERAS) and Tango Therapeutics Inc. (NASDAQ: TNGX) announced a clinical collaboration to jointly conduct clinical evaluation of the combination therapy of ERAS-0015 and vopimetostat. - Bitget
Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy - marketscreener.com
Erasca and Tango Therapeutics enter into clinical collaboration to evaluate combination of ERAS-0015 and vopimetostat - marketscreener.com
Erasca, Tango test dual-drug attack on tough pancreatic, lung cancers - Stock Titan
Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Magazine
Erasca Inc stock hits 52-week high at $14.63 By Investing.com - Investing.com Canada
Erasca stock reaches 52-week high at 12.48 USD - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Hits New 1-Year HighShould You Buy? - MarketBeat
Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Erasca, Inc. (ERAS): A Bull Case Theory - Insider Monkey
Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 - Yahoo Finance
ERAS: Lead RAS-targeted therapies show strong early data, with major trial updates expected in 2024 - TradingView
ERAS: Lead RAS-targeted therapies show promising early results, with key clinical updates expected in 2024 - TradingView
Erasca, Inc. (ERAS) Stock Analysis: Unlocking Potential in Precision Oncology with a Robust Pipeline - DirectorsTalk Interviews
Erasca Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Erasca stock hits 52-week high at $13.30 By Investing.com - Investing.com India
Assessing Erasca (ERAS) Valuation After New Pan KRAS Patent Win Through 2043 - simplywall.st
Erasca (NASDAQ:ERAS) Hits New 12-Month HighHere's What Happened - MarketBeat
Erasca stock hits 52-week high at $13.30 - Investing.com
Erasca Granted US Patent for Investigational Drug ERAS-4001 to Treat Solid Tumors - marketscreener.com
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 - Bitget
New Erasca patent protects ERAS-4001 for RAS-driven cancers to 2043 - Stock Titan
Will Erasca Inc. outperform small cap indexes2025 Pullback Review & AI Optimized Trading Strategy Guides - mfd.ru
Setup Watch: How does Erasca Inc perform in inflationary periods2025 Major Catalysts & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Erasca, Inc. (NASDAQ:ERAS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Erasca, Inc. (ERAS) Stock Analysis: Clinical-Stage Innovations with a $3.92 Billion Market Cap and High Analyst Support - DirectorsTalk Interviews
Erasca (NASDAQ:ERAS) Sets New 12-Month HighShould You Buy? - MarketBeat
Registration Momentum Builds Across the Oncology Pipeline - The Globe and Mail
Erasca Foundation plans sale of 8,333 shares | ERAS SEC FilingForm 144 - Stock Titan
Will Early ERAS-0015 Signals at Guggenheim Summit Reshape Erasca's (ERAS) RAS Pipeline Narrative? - simplywall.st
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):